Among the top 30 targets, AKT1, MDM2, and CDK2 were selected as therapeutic targets in cervical cancer due to their established roles in the regulation of apoptosis and BCL2, Caspase9, TP53 and P21 due to their established role in the regulation and progression of the cell cycle and apoptosis (Rashmi et al., 2014; Li et al., 2023; Tatekawa et al., 2024). The gene discussed is BCL2; the disease is cervical cancer.